Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-07-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
独立董事候选人声明与承诺（张汉斌）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate for a company's board, detailing qualifications, independence criteria, and compliance with regulatory requirements. It does not contain financial data, audit results, or report content. It is not an announcement of voting results or a proxy solicitation but rather a formal statement related to board/management information, specifically about a director candidate's qualifications and commitments. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on director candidacy, not a full report or announcement of a report.
2025-07-28 Chinese
董事会提名委员会工作细则
Governance Information Classification · 100% confidence The document is titled as the "Board of Directors Nomination Committee Working Rules" of 科兴生物制药股份有限公司 (Sinovac Biotech Co., Ltd.) dated July 2025. It details the structure, responsibilities, procedures, and rules of the nomination committee within the board of directors. The content focuses on governance practices related to board nominations and senior management appointments, including committee composition, decision-making processes, meeting rules, and confidentiality obligations. There is no financial data, audit information, voting results, or announcements of report publications. The document is a governance-related internal rules report, specifically about the nomination committee's working rules, which fits the definition of Governance Information (CGR). The document length is 3551 characters, which is not extremely short, and it is not an announcement or certification but a substantive governance document.
2025-07-28 Chinese
规范与关联方资金往来管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '规范与关联方资金往来管理制度' (Regulations and Management System for Related Party Fund Transactions) issued by 科兴生物制药股份有限公司. It outlines principles, procedures, responsibilities, and legal compliance related to managing funds between the company and its related parties. The content is regulatory and governance-focused, detailing internal controls, audit management, and penalties for violations. It does not contain financial statements, earnings data, or investor presentation material. It is not an announcement or a brief summary but a comprehensive governance document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-07-28 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for related party transactions (关联交易管理制度) of 科兴生物制药股份有限公司. It contains detailed internal rules, procedures, and principles regarding related party transactions, including definitions, pricing, decision-making authority, disclosure, exemptions, and responsibilities. There is no indication that this is a financial report, earnings release, or announcement of voting results. It is a governance-related document outlining internal policies and compliance with regulatory requirements. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-07-28 Chinese
信息披露管理制度
Governance Information Classification · 95% confidence The document is titled '信息披露管理制度' which translates to 'Information Disclosure Management System' for 科兴生物制药股份有限公司 (Sinovac Biotech Co., Ltd.). It is a detailed internal policy document outlining the principles, procedures, responsibilities, and regulatory compliance requirements for information disclosure by the company. It covers topics such as the types of reports to be disclosed (annual, interim, quarterly, and temporary reports), the roles of the board, management, and disclosure officers, internal controls, and legal compliance. There is no actual financial data, earnings results, or audit opinions presented. Instead, it is a governance and procedural document related to how the company manages its information disclosure obligations under Chinese securities laws and Shanghai Stock Exchange rules. Therefore, this document fits best under Governance Information (CGR), which includes reports detailing the company's internal rules, board structure, and governance practices related to disclosure.
2025-07-28 Chinese
董事会战略委员会工作细则
Governance Information Classification · 95% confidence The document is titled '董事会战略委员会工作细则' which translates to 'Board Strategic Committee Working Rules'. It outlines the structure, responsibilities, decision-making procedures, meeting rules, and other governance-related details of the company's board strategic committee. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no audit information, or any other report type. The content is focused on governance practices and internal board committee rules. Therefore, the document fits best under Governance Information (CGR). The document length is 3239 characters, which is sufficient for a detailed governance report and not a mere announcement or certification.
2025-07-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.